文献速递湿疹皮炎与荨麻疹

vIGA与BSA乘积在儿童和成人特应性皮炎中的测量性能

Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-09-01

该前瞻性皮肤科实践研究纳入653例特应性皮炎患者,评估vIGA与BSA乘积(vIGA*BSA及vIGA*cBSA)的测量性能。结果显示其与BSA、EASI、客观SCORAD有良好收敛效度,与患者报告结局弱至中等相关,具有良好的区分效度、反应度和信度,无地板/天花板效应,并建立了可解释性阈值和临床重要差异。

要点

  • vIGA*BSA与EASI、客观SCORAD收敛效度良好(ρ=0.94、0.88)
  • 与瘙痒NRS、POEM、DLQI等患者报告结局弱至中等相关
  • 信度良好(ICC 0.72-0.74),无地板/天花板效应,并建立了阈值

核心结论

  • vIGA*BSA和vIGA*cBSA在成人和儿童AD中显示良好的收敛效度、区分效度、信度、反应度和可解释性,适用于临床实践。
  • vIGA*BSA和vIGA*cBSA的收敛效度略低于EASI或客观SCORAD,但收集和评分可能更高效。

研究设计与样本

  • 前瞻性皮肤科实践研究,使用问卷和皮肤科医生评估,纳入653例成人和儿童AD患者。

主要发现

  • vIGA*BSA与BSA的Spearman ρ=0.97,vIGA*cBSA与BSA的ρ=0.93。
  • vIGA*BSA与EASI的ρ=0.94,vIGA*cBSA与EASI的ρ=0.92;与客观SCORAD的ρ分别为0.88和0.89。
  • 与平均瘙痒NRS的ρ均为0.22,与最严重瘙痒NRS的ρ分别为0.27和0.28;与POEM的ρ分别为0.44和0.43;与DLQI的ρ分别为0.48和0.49;与ItchyQOL的ρ分别为0.45和0.46;与PROMIS睡眠障碍的ρ分别为0.46和0.37;与睡眠相关损害的ρ均为0.31。
  • 信度ICC(95%CI)分别为0.72(0.60-0.81)和0.74(0.62-0.82),无地板或天花板效应。
  • 建立了可解释性 bands 和临床重要差异的阈值。

关键数值与推荐

  • vIGA*BSA与BSA的收敛效度ρ=0.97,vIGA*cBSA与BSA的ρ=0.93。
  • vIGA*BSA与EASI的ρ=0.94,vIGA*cBSA与EASI的ρ=0.92;与客观SCORAD的ρ分别为0.88和0.89。
  • 信度ICC(95%CI):vIGA*BSA为0.72(0.60-0.81),vIGA*cBSA为0.74(0.62-0.82)。
  • 与平均瘙痒NRS的ρ均为0.22,与最严重瘙痒NRS的ρ分别为0.27和0.28。

临床怎么用

  • vIGA*BSA和vIGA*cBSA可用于临床实践中评估AD严重程度,收集和评分可能更高效。
  • 可参考已建立的阈值解释评分变化和临床重要差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple clinician-reported outcome measures exist for atopic dermatitis (AD) severity. However, there is no gold standard for use in clinical practice. OBJECTIVES: To determine the measurement properties of the product of validated Investigator's Global Assessment for AD (vIGA) and body surface area (BSA) overall or divided into six categories (cBSA: 0%/0.1, <10%/10, <30%/30, <50%/50, <70%/70 and <90%/90-100%) and compare with other clinician-reported and patient-reported outcomes in adults and children with AD. METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n = 653). RESULTS: vIGA*BSA and vIGA*cBSA had good convergent validity with BSA (Spearman's ρ = 0.97 and 0.93), eczema area and severity index (ρ = 0.94 and 0.92), and objective SCORAD (ρ = 0.88 and 0.89); and weak-to-good convergent validity with Numeric Rating Scale average itch (ρ = 0.22 and 0.22) and worst itch (ρ = 0.27 and 0.28), Patient-Oriented Eczema Measure (ρ = 0.44 and 0.43), Dermatology Life Quality Index (ρ = 0.48 and 0.49), ItchyQOL (ρ = 0.45 and 0.46), PROMIS Sleep Disturbance (ρ = 0.46 and 0.37) and sleep-related impairment (ρ = 0.31 and 0.31) in adults and/or children; very good discriminant validity for physician-reported global AD severity; good responsiveness to change of severity of AD and itch; and good reliability (intraclass correlation coefficient [95% confidence interval]: 0.72 [0.60-0.81] and 0.74 [0.62-0.82]) with no floor or ceiling effects. Thresholds for interpretability bands and clinically important difference were established. CONCLUSIONS: vIGA*BSA and vIGA*cBSA scores showed good convergent and discriminant validity, reliability, responsiveness and interpretability in adults and children with AD, and were feasible for use in clinical practice. vIGA*BSA and vIGA*cBSA had slightly lower convergent validity than EASI or objective SCORAD, but might be more efficient to collect and score.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Lei D, Yousaf M, et al. Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis. J Eur Acad Dermatol Venereol. 2020. PMID: 32745300. doi:10.1111/jdv.16846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。